Literature DB >> 16710680

[Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

A Böhle1, H Suttmann, S Brandau.   

Abstract

Immunotherapy for treatment of solid cancer mostly is an experimental treatment. In contrast, intravesical immunotherapy of superficial bladder cancer with bacille Calmette-Guérin (BCG) is clinically well established and accepted worldwide because of better results compared to topical chemotherapy. BCG is currently regarded as the most successful immunotherapy of cancer. Unfortunately the mechanism of action has not yet been fully clarified. This article gives an overview on the complex research on the mechanisms of actionhighly successful therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16710680     DOI： 10.1007/s00120-006-1059-x

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  67 in total

1.  Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy.

Authors:  Fabien Saint; Nathalie Kurth; Pascale Maille; Dimitri Vordos; Andre Hoznek; Pascale Soyeux; Jean Jacques Patard; Claude C Abbou; Dominique K Chopin
Journal:  Int J Cancer       Date:  2003-11-10       Impact factor: 7.396

2.  Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.

Authors:  S Brandau; H Suttmann; J Riemensberger; U Seitzer; J Arnold; C Durek; D Jocham; H D Flad; A Böhle
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

3.  Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.

Authors:  L R Kavoussi; E J Brown; J K Ritchey; T L Ratliff
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

4.  T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.

Authors:  F Saint; J J Patard; P Maille; P Soyeux; A Hoznek; L Salomon; A De La Taille; C C Abbou; D K Chopin
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

5.  5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.

Authors:  P U Malmström; H Wijkström; C Lundholm; K Wester; C Busch; B J Norlén
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

6.  The inhibitory effects of interferon gamma on the growth of bladder cancer cells.

Authors:  S J Hawkyard; A M Jackson; K James; S Prescott; J F Smyth; G D Chisholm
Journal:  J Urol       Date:  1992-05       Impact factor: 7.450

7.  Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.

Authors:  A Morales; J L Chin; E W Ramsey
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

8.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

9.  Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

Authors:  Aaron T Ludwig; Jill M Moore; Yi Luo; Xiaohong Chen; Nicole A Saltsgaver; Michael A O'Donnell; Thomas S Griffith
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

10.  The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells.

Authors:  A Thanhäuser; A Böhle; B Schneider; N Reiling; T Mattern; M Ernst; H D Flad; A J Ulmer
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968
View more
  2 in total

1.  Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer.

Authors:  Rama Devi Mittal; Ruchika Gangwar; Raju K Mandal; Priyanka Srivastava; Dinesh K Ahirwar
Journal:  Mol Biol Rep       Date:  2011-05-27       Impact factor: 2.316

Review 2.  The use of botulinum neurotoxin type a in a patient with refractory urge incontinence to facilitate the intravesical treatment of bladder carcinoma.

Authors:  Mina Fam; Patricia Gilhooly
Journal:  Rev Urol       Date:  2014
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.